Product Information
ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR is a generic product labeled by CELLTRION USA, Inc., priced at $490.0367 per EA under NDC 72606002210. Its NADAC has been published 33 times since Feb 18, 2026.
Manufacturer
CELLTRION USA, Inc.NDC
72606002210
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761219On Market Since
11/30/2023
Price Statistics
The NADAC for ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $490.0367 per EA |
|---|---|
| All-time high | $495.3681 (Apr 15, 2026) |
| All-time low | $490.0367 (Sep 23, 2026) |
| 52-week high | $495.3681 |
| 52-week low | $490.0367 |
| Median price | $494.1778 |
| Average price | $493.7421 |
| Largest weekly change | +0.4% (Mar 18, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
CELLTRION USA, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
adalimumab-aaty market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR?
The current National Average Drug Acquisition Cost (NADAC) for ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR, manufactured by CELLTRION USA, Inc., is $490.0367 per EA (NDC 72606002210), effective Sep 30, 2026.
How has the price of ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR changed over time?
Over the history we have for it, the NADAC for ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR?
Since Feb 18, 2026, the NADAC for ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR has ranged from a low of $490.0367 (Sep 23, 2026) to a high of $495.3681 (Apr 15, 2026), with a median of $494.1778 per EA.
Are there cheaper alternatives to ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR in a comparable dosage form, but none are currently priced below it.
Who manufactures ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR?
ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR (NDC 72606002210) is labeled by CELLTRION USA, Inc., and CMS classifies it as a generic product.